Japan, Oct. 5 -- NOVARTIS AG,TRUSTEES OF THE UNIV OF PENNSYLVANIA,UNIV OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION has got intellectual property rights for 'TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR.' Other related details are as follows:
Application Number: JP,2024-102953
Category (FI): A61K31/7088,A61K35/17,A61K35/76,A61K35/761,A61K39/395@D,A61K39/395@N,A61K40/10,A61K40/11,A61K40/31,A61K40/42,A61K40/50,A61K45/00,A61K48/00,A61P25/00,A61P35/00,A61P35/04,A61P37/04,A61P43/00,121,C07K14/725,C07K16/28,C07K19/00,C12N15/12,C12N15/13,C12N15/62@Z,C12N5/0783,C12N5/10
Stage: Grant (IP right granted following substantive examination.)
Filing Date: June 26, 2024
Publication Date: Sept. 26, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
